Ardelyx (NASDAQ:ARDX) Announces Earnings Results, Misses Expectations By $0.02 EPS

Ardelyx (NASDAQ:ARDX) released its earnings results on Friday. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02), MarketWatch Earnings reports. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.60 million.

ARDX traded down $0.06 during trading on Friday, hitting $2.28. 70,044 shares of the company’s stock were exchanged, compared to its average volume of 87,874. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 0.58. Ardelyx has a 1 year low of $1.60 and a 1 year high of $4.60. The stock’s 50 day moving average is $2.52. The stock has a market capitalization of $140.23 million, a price-to-earnings ratio of -1.41 and a beta of 1.87.

In other Ardelyx news, CEO Michael Raab sold 10,054 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $2.54, for a total transaction of $25,537.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have sold 18,787 shares of company stock valued at $47,753. 15.31% of the stock is owned by insiders.

Separately, ValuEngine upgraded shares of Ardelyx from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $8.08.

Ardelyx Company Profile

Ardelyx, Inc, a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis.

Read More: What is a Real Estate Investment Trust (REIT)?

Earnings History for Ardelyx (NASDAQ:ARDX)

Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with's FREE daily email newsletter.